Introduction: Atypical parkinsonism is a neurodegenerative disease that includes diverse neurological and psychiatric manifestations.
Early-onset parkinsonism (EOP) is a neurodegenerative disease characterized by the young-onset presentations of tremor, muscular rigidity, postural instability, and slowing of movements. 1 The most common cause of parkinsonism is Parkinson's disease (PD), accounting for approximately 80% of the cases with parkinsonism. Atypical juvenile parkinsonism (AJP) usually refers to a complex form of EOP that is inherited in a recessive manner and manifests with diverse neurological and psychiatric manifestations, including pyramidal signs, abnormalities of eye movements, depression, anxiety, psychosis, impulse control disorders, and intellectual disability (ID), among others. 2 To date, pathogenic mutations in at least eight different genes have been reported in AJP. These [2] [3] [4] [5] [6] [7] ID is characterized by below-average intelligence or mental ability to perform activities of daily living. It is well known that some patients with parkinsonism may manifest ID or some kind of cognitive dysfunction. For instance, patients with null DNAJC6 mutations or large DNAJC6 deletions may develop ID with or without parkinsonism. 8, 9 More recently, two other genes have 11, 12 and RARB [3p24.2; MIM# 615524], mutations of which have been found in patients with microphthalmia, ID, and progressive motor impairment. 13 The goal of this study was to identify the diseasecausing mutations in a consanguineous family with 2 affected siblings featuring ID and parkinsonism without mutations in known genes.
Patients and Methods

Subjects
An Iranian consanguineous family featuring earlyonset autosomal-recessive parkinsonism and ID was clinically examined. The family consisted of healthy parents, 2 affected sons, and an unaffected daughter (Fig. 1A) . DNA samples from probands of 15 unrelated families with ID and a movement disorder phenotype and from 504 ethnicity-matched control individuals were as well available. The local ethics committee at Shahid Beheshti University of Medical Sciences approved this study, and informed consent according to the Declaration of Helsinki was obtained from all participants. DNA samples from all participants were isolated from whole blood using standard procedures.
Clinical Evaluation
All participants underwent a series of structured questionnaires and a comprehensive neurological and neuropsychological assessment undertaken at the movement disorders unit by three experienced movement disorder specialists. The performed neuropsychological examinations are fully described in the Supporting Information. Conservation among other orthologous of the two reported PTRHD1 mutations. The mutation reported in this study is highlighted in red whereas the mutation reported by Jaberi and colleagues is highlighted in blue.
Homozygosity Mapping
High-throughput single-nucleotide polymorphism (SNP) genotyping was carried out in all available family members (Fig. 1A ) by using the HumanOmniExpress Exome arrays (v1.3) and HiScanSQ system (Illumina Inc., San Diego, CA). Genotyping data were used to perform homozygosity mapping (HM) as previously described (Fig. 1B) . 3 
Whole-Genome Sequencing
Whole-genome sequencing (WGS) was carried out at the New York Genome Center in the two affected family members (II-I and II-II) as described in the Supporting Information.
Validation and Disease-Segregating Analyses
Primer sequences for the entire coding region of the PTRHD1 gene, which stands for peptidyl-tRNA hydrolase domain containing 1, were designed by using a public primer design website (http://ihg.gsf.de/ihg/ExonPrimer. html). Direct Sanger sequencing using primers flanking the exon 1 of the PTRHD1 (C2orf79) gene was used to validate the c.157C>T mutation (Fig. 1C) . Once validated, the mutation was examined in available family members for disease segregation analyses. The entire PTRHD1 gene was examined in 15 familial cases with ID and a movement disorder phenotype, including parkinsonism and/or tremor. The PTRHD1 exon 1 was additionally examined in 104 Iranian control individuals through Sanger sequencing and in 400 Iranian control individuals through allelespecific amplification. For Sanger assays, all purified polymerase chain reaction (PCR) products were sequenced, resolved, and analyzed as previously described. 3 Allelespecific detection was performed using designed primers for the identified mutation, and PCR products were analyzed by agarose gel electrophoresis.
Results
Patients' Clinical Details
The proband (II-I) presented with ID, muscle stiffness, rest and postural tremor, postural instability, gait disturbances, speech difficulties, as well as psychiatric symptoms, such as anxiety, hypersomnia, and hypersexuality. His brother showed similar symptoms, but milder, and no additional family members were affected. Full patient's clinical details are described in the Supporting Information.
Molecular Analyses
The performed HM identified a total of six potential disease-associated loci shared only by the two affected individuals (Supporting Table 1 ). WGS was then performed on the two affected individuals (II-I and II-II). After filtering for common genetic variation, 194 genomic variations, including missense (n 5 133), frameshift, splice-site, stop-gained, and start-lost (n 5 61) mutations, were found to be present in both patients. Among these, only a homozygous missense mutation was located in one of the six previously identified disease-associated loci (Fig. 1B) . No other homozygous or compound heterozygous mutations were identified outside the disease-associated loci. We then investigated whether genomic deletions to be shared exclusively by affected individuals might as well be causative; however, no genomic deletions were found in the identified disease-associated homozygous segments, and no common genomic deletions were identified within the exome. Because of the presence of parkinsonism in both the affected individuals, PDand parkinsonism-associated loci were as well examined, but no shared region of homozygosity was observed within the known parkinsonism loci, and no pathogenic mutation was identified within the known PD and parkinsonism genes.
The only homozygous mutation identified in a previously identified disease-associated locus was located in the PTRHD1 gene (C2orf79) at chromosome 2p23.3. It consisted in a C to T transition at nucleotide 157 (c.157C>T), leading to the p.His53Tyr change on the protein level. This mutation did segregate perfectly with disease status and was found to be highly conserved among other orthologous (Fig.  1A-C) . In addition, it was predicted to be pathogenic The mutation identified in this study is shown in bold.
a These control individuals were sequenced in this study because Jaberi and colleagues did not report control data for this specific mutation. PTH2, peptidyl-tRNA hydrolase 2.
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by various computational methods, was not previously reported, and was not found in any public singlenucleotide variant (SNV) database, including the National Heart, Lung and Blood Institute Grand Opportunity Exome Sequencing Project and the Exome Aggregation Consortium (ExAC; exac.broadinstitute.org) ( Table 1 ). The PTRHD1 c.157C>T mutation was then examined in 504 ethnicitymatched neurologically normal individuals and found to be absent in 1,008 control chromosomes, further supporting its pathogenicity. Fifteen additional families with ID and a movement disorder were selected and screened for PTRHD1 mutations; however, no pathogenic PTRHD1 mutation was identified in these newly recruited cases.
Discussion
Here, we describe the identification of a novel causative gene for a complex form of autosomal-recessive ID with parkinsonism. The combination of HM and WGS led us to assign the chromosome 2p23.3 locus as the disease-associated locus and identify a homozygous variation in the PTRHD1 gene as the diseasecausing mutation ( Fig. 1; Table 1 ). The diseasesegregating PTRHD1 mutation, predicted to be pathogenic by various computational methods, was shown to be absent in over 1,000 ethnicity-matched control chromosomes and SNV public databases, likely supporting its pathogenicity.
Despite PTRHD1 mutations having never been reported in parkinsonism or ID, deletions at the 2p23 locus, encompassing the PTRHD1 gene, are known to be associated with several ID syndromes (Supporting Table 2 ).
14-20 Furthermore, Jaberi and colleagues recently identified a missense PTRHD1 mutation (c.155G>A; p.Cys52Tyr) in a family with early-onset parkinsonism and cognitive dysfunction. 21 Although they claimed that the strongest candidate gene for the disease was ADORA1 attributed to the role of adenosine receptors in brain function and neuronal activity, there were no substantial proofs to discard PTRHD1 as a causative gene, as was well acknowledged in their report. 21 The PTRHD1 p.Cys52Tyr mutation was predicted to be pathogenic by various computational methods, was found with extremely low frequency in public SNV databases, and was absent in 208 ethnicity-matched control chromosomes sequenced by us (Table 1) . In any case, to exclude ADORA1 as a causative gene, we further investigated the coverage of ADORA1 gene in our SNP genotyping and WGS data. A total of 33 SNPs covering the ADORA1 locus were genotyped, with only 63% of the SNPs being homozygous for Patient 1 (Supporting Table 3 ), further excluding ADORA1 as the disease-associated locus. Sequencing of the ADORA1 gene at more than 30 3 coverage identified no pathogenic mutations, further supporting the role of PTRHD1 as a causative gene in both the reported families.
Although little is known about the function of PTRHD1, both PTRHD1 mutations identified in families with ID and parkinsonism lie within the PTH2 domain (25-139 amino acids) of the PTRHD1 protein ( Table 1 ). The PTH2 domain is a ubiquitin-like (UBL) domain-binding protein that is known to participate in the ubiquitin-proteasome pathway and has been shown to suppress ubiquitin-mediated degradation. 22 In yeast, overexpression of PTH2 has been shown to cause accumulation of polyubiquitinated proteins and inhibit growth. It is also known that PTH2 binds to the UBL domain of Rad23 and Dsk2 and interacts with polyubiquitinated proteins through their ubiquitin-associated domains. 22 The role of ubiquitinmediated proteolysis in the pathogenesis of ID and neurodegenerative diseases, such as PD and Alzheimer's disease, is well known and documented. 23 Indeed, PD is characterized by the loss of dopaminergic neurons and the progressive neuronal accumulation of protein inclusions containing alpha-synuclein and ubiquitin 24 ; two different protein ubiquitin ligases (Parkin and FBXO7) are well established as causative genes for early-onset forms of parkinsonism 2, [25] [26] [27] ; and overexpression of mutant alpha-synuclein as well as downregulation of Parkin have been shown to increase sensitivity to proteasome inhibitors, decreasing proteasomal function. 28 Moreover, mutations in various ubiquitin enzymes participating in the ubiquitin-proteasome system are known to be associated with the pathophysiology of ID. This is the case of UBE3A (MIM# 105830), mutations of which cause Angelman syndrome, 29 as well as UBE2A (MIM# 300860), CUL4B (MIM# 300354), and BRWD3 (MIM# 300659), mutations of which are known to cause X-linked ID syndromes. [30] [31] [32] Therefore, given the role that the ubiquitin proteasome system plays in brain development, synaptic plasticity, and long-term memory formation, 33 and the previous association of the chromosome 2p23.3 locus with ID, we speculated that PTRHD1 genetic variability might cause ID and parkinsonism through defects in the ubiquitin-proteasome system, as observed in other inherited forms of parkinsonism and ID.
In conclusion, this study describes, for the first time, the association of PTRHD1, known to participate in the ubiquitin-proteasome pathway, with the pathogenesis of ID and parkinsonism.
